Form 4: Kairos Pharma Director Acquires 29,084 RSUs

Kairos Pharma Director Hyun W. Bae reported the acquisition of 29,084 Restricted Stock Units under the company's 2023 Equity Incentive Plan.

Summary

• Hyun W. Bae, a Director of Kairos Pharma, LTD. (KAPA), reported two transactions involving Restricted Stock Units (RSUs).
• On September 16, 2025, 10,000 RSUs were acquired, granted on September 16, 2024, under the 2023 Equity Incentive Plan, vesting annually in three substantially equal installments commencing on the IPO anniversary.
• Following this transaction, beneficial ownership was 54,286 securities, comprising 47,620 shares of common stock and 6,666 unvested RSUs.
• On October 8, 2025, an additional 19,084 RSUs were acquired under the same plan, scheduled to vest in full on the first anniversary of the grant date.
• After the second transaction, total beneficial ownership increased to 73,370 securities, consisting of 54,286 shares of common stock and 19,084 unvested RSUs.
• All RSUs were acquired at a price of $0.00, indicating they are part of an equity compensation plan.

Sentiment

Score: 7

Explanation: The acquisition of Restricted Stock Units by a director generally indicates confidence in the company's future and aligns management's interests with shareholders. While not a direct cash investment, it represents a commitment to the company's long-term success through equity compensation.

Positives

• Director Hyun W. Bae acquired a total of 29,084 Restricted Stock Units (RSUs), aligning management interests with shareholder value.
• The RSUs are issued under the company's 2023 Equity Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• No direct negatives are presented in this Form 4 filing, which primarily reports insider transactions.

Risks

• No specific risks are detailed in this Form 4 filing.

Future Outlook

The vesting schedules for the acquired Restricted Stock Units (RSUs) extend into the future, with the 10,000 RSUs vesting annually in three substantially equal installments commencing on the IPO anniversary (September 16, 2025), and the 19,084 RSUs vesting in full on the first anniversary of their grant date (October 8, 2025).

Industry Context

The acquisition of Restricted Stock Units by a director is a common practice in the biotechnology and pharmaceutical industry, often used to align executive compensation with long-term company performance and shareholder interests, especially for companies that have recently undergone an IPO like Kairos Pharma.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice across various industries, including biotech, to incentivize long-term performance and retention.
• The vesting schedules, particularly the multi-year annual vesting for the IPO-related grant, are typical for aligning director interests with sustained company growth post-IPO.
• The grant price of $0.00 for RSUs is standard, as RSUs represent a promise to deliver shares upon vesting, rather than an immediate purchase.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholder value through equity ownership.
• Employees: The equity incentive plan provides a framework for compensation that can motivate performance.

Next Steps

• The 10,000 RSUs will vest annually in three substantially equal installments commencing on September 16, 2025.
• The 19,084 RSUs are scheduled to vest in full on October 8, 2026 (first anniversary of grant date).

Key Dates

Recommendation

The filing reports a director's acquisition of Restricted Stock Units (RSUs) as part of an equity incentive plan. While this indicates management's alignment with long-term company performance and is generally a positive signal of insider confidence, it does not provide new fundamental financial data or strategic shifts that would warrant a 'buy' or 'sell' recommendation based solely on this Form 4. Investors should 'hold' and consider this information in conjunction with broader financial performance, market conditions, and company-specific news.

Keywords

Kairos Pharma, KAPA, Hyun W. Bae, Director, Form 4, SEC filing, Restricted Stock Units, RSUs, Equity Incentive Plan, Insider Transaction, Beneficial Ownership